npj Precision Oncology is a new open-access journal committed to publishing cutting edge scientific research in all aspects of precision oncology from basic science to translational applications, to clinical medicine.
npj Precision Oncology is an international, peer-reviewed journal committed to publishing cutting-edge scientific research in all aspects of precision oncology from basic science to translational applications to clinical medicine. The journal defines precision oncology as cancer diagnosis, prognosis, preventio...
2022npj Precision Oncology doi:10.1038/s41698-022-00254-ypmid:35228642 Patients with advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer who are prescribed ALK-tyrosine kinase inhibitors (ALK-TKIs) rarely have complete responses, with residual tumors relapsing as heterogeneous...
2. In 2023, there were an estimated 153,000 new CRC cases in the United States alone3, making clinical developments a priority for this disease.
npj Breast Cancerhas a 2-year impact factor of 5.9 (2022), article downloads of 742,276 (2022) and 7 days from submission to first editorial decision (2022). Call for papers: AI in precision oncology Submit to our new collection focused on AI in precision oncology, deadline: 19 October...
Volume 7, article number75, (2023) Cite this article Download PDF You have full access to thisopen accessarticle npj Precision Oncology Yujun Xu, Xiaoliang Shi, Weifeng Wang, Lin Zhang, Shinghu Cheung, Marion Rudolph, Nicoletta Brega,
documents published in that journal. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. The two years line is equivalent to journal impact factor ™ (Thomson Reuters) ...
npj Precision Oncology volume 7, Article number: 78 (2023) Cite this article 9234 Accesses 21 Citations 18 Altmetric Metrics details Abstract High-grade glioma is one of the deadliest primary tumors of the central nervous system. Despite the many novel immunotherapies currently in development, it...
The immunosuppressive tumor microenvironment (TME) in PDAC, a major factor contributing to immunotherapy resistance, includes tumor-infiltrating immune-suppressive cells, stromal cells, the microbiome, and the extracellular matrix (ECM). The immune infiltration in PDAC is characterized by an abundance of...
npj Precision Oncology volume 8, Article number: 35 (2024) Cite this article 4283 Accesses Metrics details Abstract Effective targeting of cancer-associated fibroblasts (CAFs) is hindered by the lack of specific biomarkers and a poor understanding of the mechanisms by which different populations of...